Literature DB >> 1279128

T cell responses to myelin proteins in Guillain-Barré syndrome.

A Khalili-Shirazi1, R A Hughes, S W Brostoff, C Linington, N Gregson.   

Abstract

We have investigated the hypothesis that the pathogenesis of Guillain-Barré syndrome (GBS) involves an autoimmune T cell response to P0 and P2 proteins of peripheral nerve myelin. The proliferative responses of blood mononuclear cells (MNC) to myelin proteins and synthetic peptides derived from them were determined in patients with GBS and chronic idiopathic demyelinating polyradiculoneuropathy (CIDP), normal controls (NC) and patients with other neuropathies (ONP). Twelve out of 19 GBS patients responded to P0 or P2, 6 to P0 and its peptides only, 3 to P2 and its peptides only, and 3 to both P0 and P2 antigens. Responses to at least one of the antigens were also found in 6/13 of CIDP patients, but in only 4/17 NC and 2/6 ONP. Immune responses in GBS are heterogeneous. The early T cell responses to P0 protein, described here for the first time, may be important in the pathogenesis of some cases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1279128     DOI: 10.1016/0022-510x(92)90069-w

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  13 in total

Review 1.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Clinical utility of autoantibodies in Guillain-Barre syndrome and its variants.

Authors:  J W Terryberry; Y Shoenfeld; J B Peter
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 3.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

4.  T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  P A Csurhes; A-A Sullivan; K Green; M P Pender; P A McCombe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

5.  Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins.

Authors:  Mohamed Mahdi-Rogers; Yusuf A Rajabally
Journal:  Biologics       Date:  2010-03-24

Review 6.  Guillain-Barré syndrome, transverse myelitis and infectious diseases.

Authors:  Yhojan Rodríguez; Manuel Rojas; Yovana Pacheco; Yeny Acosta-Ampudia; Carolina Ramírez-Santana; Diana M Monsalve; M Eric Gershwin; Juan-Manuel Anaya
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

7.  Cellular mRNA expression of interferon-gamma, IL-4 and transforming growth factor-beta (TGF-beta) by rat mononuclear cells stimulated with peripheral nerve myelin antigens in experimental allergic neuritis.

Authors:  J Zhu; E Mix; T Olsson; H Link
Journal:  Clin Exp Immunol       Date:  1994-11       Impact factor: 4.330

Review 8.  The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Kathleen M Hagen; Shalina S Ousman
Journal:  J Neuroinflammation       Date:  2021-03-22       Impact factor: 8.322

9.  Immune dysregulation in patients with carpal tunnel syndrome.

Authors:  Gila Moalem-Taylor; Benny Baharuddin; Barbara Bennett; Arun V Krishnan; William Huynh; Matthew C Kiernan; Cindy Shin-Yi Lin; Boaz Shulruf; Elizabeth Keoshkerian; Barbara Cameron; Andrew Lloyd
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

10.  A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy.

Authors:  Cédric Louvet; Beniwende G Kabre; Dan W Davini; Nicolas Martinier; Maureen A Su; Jason J DeVoss; Wendy L Rosenthal; Mark S Anderson; Hélène Bour-Jordan; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2009-02-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.